Alzheimer's research links sugar metabolism and glucosamine to disease progression

Research published in Nature Metabolism suggests that metabolic alterations, specifically a phenomenon known as hyperglycosylation, may play an active role in the progression of Alzheimer's disease. This process involves an increase in the production of glycans—carbohydrate structures that attach to proteins—within affected brain tissues. In animal models, researchers found that reducing the activity of the PGM3 enzyme or using pharmacological strategies to decrease N-glycosylation improved memory performance.

Complementary retrospective analysis conducted by University of Florida researchers examined the impact of glucosamine, a common over-the-counter joint supplement. The study, which analyzed UF Health medical records from 2012 to 2024, linked glucosamine use to a faster progression from mild cognitive impairment to dementia. Additionally, the findings indicated an increased mortality risk in patients with already diagnosed neurodegenerative disorders. While the animal studies suggest metabolic intervention could be beneficial, the human findings regarding glucosamine remain observational and require further clinical confirmation.